Novo Nordisk A/S has estimated that sales will grow by 9 to 10% in 2010 based on continued market penetration of its core diabetes products and its new glucagon-like peptide-1 receptor agonist for Type 2 diabetes, Victoza (liraglutide). ---Subscribe to MedNous to access this article--- Company News
